纳武单抗治疗复发霍奇金淋巴瘤

T. Valiev, A. Odzharova
{"title":"纳武单抗治疗复发霍奇金淋巴瘤","authors":"T. Valiev, A. Odzharova","doi":"10.17650/2782-3202-2022-2-2-38-44","DOIUrl":null,"url":null,"abstract":"The incidence of Hodgkin lymphoma (HL) relapses is 8-30 % and depend on disease stage, presence of unfavorable prognostic factors and treatment programme. Modern second-line treatment programmes are based on gemcitabine and carboplatin with following autologous stem cell transplantation and can reach many-year overall survival in 70 % of patients. For increasing treatment efficacy of relapsed HL monoclonal antibodies (brentuximab vedotin) and checkpoint inhibitors (nivolumab) are supplemented. Nowadays it makes an assessment of immunochemotherapy efficacy in patients with relapsed HL, determines long-term effects of treatment. Nevertheless, preliminary results allow to find a significant therapeutic advantages of immunochemotherapy with following autologous stem cell transplantation above standard polychemotherapy.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"196 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nivolumab in treatment of relapsed Hodgkin lymphoma\",\"authors\":\"T. Valiev, A. Odzharova\",\"doi\":\"10.17650/2782-3202-2022-2-2-38-44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The incidence of Hodgkin lymphoma (HL) relapses is 8-30 % and depend on disease stage, presence of unfavorable prognostic factors and treatment programme. Modern second-line treatment programmes are based on gemcitabine and carboplatin with following autologous stem cell transplantation and can reach many-year overall survival in 70 % of patients. For increasing treatment efficacy of relapsed HL monoclonal antibodies (brentuximab vedotin) and checkpoint inhibitors (nivolumab) are supplemented. Nowadays it makes an assessment of immunochemotherapy efficacy in patients with relapsed HL, determines long-term effects of treatment. Nevertheless, preliminary results allow to find a significant therapeutic advantages of immunochemotherapy with following autologous stem cell transplantation above standard polychemotherapy.\",\"PeriodicalId\":318498,\"journal\":{\"name\":\"MD-Onco\",\"volume\":\"196 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MD-Onco\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/2782-3202-2022-2-2-38-44\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MD-Onco","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/2782-3202-2022-2-2-38-44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

霍奇金淋巴瘤(HL)复发的发生率为8- 30%,取决于疾病分期、不良预后因素的存在和治疗方案。现代二线治疗方案以吉西他滨和卡铂为基础,随后进行自体干细胞移植,70%的患者可达到多年的总生存期。为了提高复发性HL单克隆抗体(brentuximab vedotin)和检查点抑制剂(nivolumab)的治疗效果。目前对复发HL患者的免疫化疗疗效进行评价,确定治疗的远期效果。然而,初步结果发现自体干细胞移植后免疫化疗比标准多化疗有显著的治疗优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Nivolumab in treatment of relapsed Hodgkin lymphoma
The incidence of Hodgkin lymphoma (HL) relapses is 8-30 % and depend on disease stage, presence of unfavorable prognostic factors and treatment programme. Modern second-line treatment programmes are based on gemcitabine and carboplatin with following autologous stem cell transplantation and can reach many-year overall survival in 70 % of patients. For increasing treatment efficacy of relapsed HL monoclonal antibodies (brentuximab vedotin) and checkpoint inhibitors (nivolumab) are supplemented. Nowadays it makes an assessment of immunochemotherapy efficacy in patients with relapsed HL, determines long-term effects of treatment. Nevertheless, preliminary results allow to find a significant therapeutic advantages of immunochemotherapy with following autologous stem cell transplantation above standard polychemotherapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信